Second Quarter 2014 Results Total revenue for the next quarter of 2014 was $68.2 million, an increase of 15 percent in comparison to total revenue of $59.3 million reported in the next quarter of 2013. Total contract income for the next quarter of 2014 was $61.5 million, a rise of 21 percent in comparison to contract revenue of $50.8 million reported in the second quarter of 2013. Agreement margins were 26.7 percent for the next quarter of 2014, compared with 16.4 percent for the next one fourth of 2013, driven by increased capability utilization and the addition of Cedarburg Pharmaceuticals. Royalty revenue in the second quarter of 2014 was $6.7 million, a decrease of 21 percent from $8.5 million in the next quarter of 2013.5 million from the web product sales of certain amphetamine salts sold by Actavis.However, the restrictions of the post hoc analysis ought to be stressed. The rate of all-cause prophylaxis failure among patients who received placebo was higher in our trial than in various other CMV prophylaxis trials .10-13 However, inside our principal analysis, all-cause prophylaxis failure included discontinuation of the study drug for any reason . Although all-cause failure, which was used in this trial, is normally a conservative measure of treatment failure, similar trials have typically compared rates of virologic failing in the primary analysis.